Protocols

CRISPR Therapeutics, Casebia ink AAV deal with StrideBio; Puma gets an AdComm date; Merrimack names new R&D chief

CRISPR Therapeutics $CRSP and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG, have inked a collaboration agreement with StrideBio to develop AAV vectors for in vivo gene delivery applications. StrideBio’s task will be to develop “vectors with improved properties such as tissue specificity and reduced susceptibility to immune responses.”

→ The Oncologic Drugs Advisory Committee (ODAC) will meet on May 24 to discuss Puma’s $PBYI application for its cancer drug neratinib.

→ Cambridge, MA-based Merrimack Pharmaceuticals $MACK appointed Daryl Drummond as its new head of research. Drummond’s last post at the company was as Vice President of Discovery and Team Leader for Merrimack’s early-stage pipeline.

→ Vancouver-based Zymeworks has set terms for its looming IPO. The biotech aims to raise around $65 million by selling 4.5 million shares at $13 to $16 each. And insiders have dibs on $42 million of that, abut two-thirds of the total.

→ Brisbane, CA-based Aimmune Therapeutics named Eric Bjerkholt as Chief Financial Officer. Bjerkholt joins Aimmune from Sunesis Pharmaceuticals.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BioNJ CEO Summit 2017